LivaNova PLC has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005720/en/
“This is a critical milestone in our ongoing commitment to provide access to Perceval within the Chinese cardiac surgery community and to patients, who ultimately benefit the most,” said Roy Khoury, LivaNova’s President of the International Region.
The PERFECT trial is expected to enroll approximately 160 patients who will receive five years of follow-up at eight investigational sites in China. The primary endpoint of the trial is a one-year composite endpoint of major cardiac events as per the Clinical Events Committee adjudication.
“Through the PERFECT trial, we reinforce our commitment to market expansion and take another important step toward meeting the increasing global need for advanced aortic valve solutions,” said Alistair Simpson, General Manager of LivaNova’s Cardiac Surgery business franchise. “We are eager to enhance patient care through expanded access to our truly sutureless valve technology.”
Perceval is specifically designed to reduce the physiological impact of aortic valve replacement, simplify complex and minimally invasive procedures, and improve patient outcomes. The Perceval sutureless valve has become a trusted platform supported by a strong body of evidence and more than 10 years of clinical experience.
“We greatly look forward to the possibility of making this innovative technology, which has demonstrated excellent outcomes in Europe and the United States, available to patients in China,” said Professor Shengshou Hu, Principal Investigator and President of Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing, China. “The excellent hemodynamic characteristics of the Perceval valve, along with its suitability for less invasive approaches, makes introduction of this valve to the greater Chinese population particularly appealing.”
The highly versatile, truly sutureless Perceval biological valve has optimized aortic valve surgery. Perceval reflects LivaNova’s continued innovation and commitment to improving surgical outcomes and long-term survival, while providing surgeons with a trusted and highly durable cardiac surgery platform.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 4,500 employees, inclusive of approximately 900 employed by our CRM business franchise. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com.
